Copyright
©The Author(s) 2024.
World J Hepatol. Jan 27, 2024; 16(1): 91-102
Published online Jan 27, 2024. doi: 10.4254/wjh.v16.i1.91
Published online Jan 27, 2024. doi: 10.4254/wjh.v16.i1.91
Table 4 Summary of adverse events occurring in either group of the trials included in this meta-analysis
| Ref. | Group | Patients | AE | ||||||||
| Any | Grade ≥ 3 | HFSR | Diarrhoea | Hypertension | Fatigue | Alopecia | Abdominal pain | Vomiting | |||
| Koch et al[19], 2021 | Sorafenib + TACE | 50 | 43 (86) | 17 (34) | 12 (24) | 13 (26) | NA | 3 (6) | NA | 14 (41) | 5 (14) |
| Sorafenib alone | 78 | 62 (80) | 25 (32) | 13 (17) | 17 (22) | NA | 6 (8) | NA | 0 (0) | 0 (0) | |
| Park et al[20], 2019 | Sorafenib + TACE | 153 | 148 (97) | NA | 74 (48) | 60 (39) | 27 (18) | 24 (16) | 23 (15) | 82 (54) | 31 (20) |
| Sorafenib alone | 167 | 151 (90) | NA | 88 (53) | 54 (32) | 23 (14) | 24 (14) | 25 (15) | 29 (17) | 11 (7) | |
| Kok et al[23], 2019 | Sorafenib + TACE | NA | |||||||||
| Sorafenib alone | NA | ||||||||||
| Wu et al[21], 2017 | Sorafenib + TACE | 56 | NA | 13 (23) | 30 (54) | 25 (45) | 13 (23) | 12 (21) | 4 (7) | NA | 31 (55) |
| Sorafenib alone | 48 | NA | 14 (29) | 36 (75) | 27 (56) | 22 (46) | 12 (25) | 3 (6) | NA | 27 (56) | |
| Zhang et al[22], 2015 | Sorafenib + TACE | 45 | NA | 12 (27) | 29 (64) | 20 (44) | 1 (2) | 11 (24) | 25 (56) | 26 (58) | 21 (47) |
| Sorafenib alone | 44 | NA | 6 (14) | 26 (59) | 19 (43) | 2 (5) | 12 (27) | 22 (50) | 0 (0) | 0 (0) | |
- Citation: Yang HJ, Ye B, Liao JX, Lei L, Chen K. Sorafenib plus transarterial chemoembolization vs sorafenib alone for patients with advanced hepatocellular carcinoma: A systematic review and meta-analysis. World J Hepatol 2024; 16(1): 91-102
- URL: https://www.wjgnet.com/1948-5182/full/v16/i1/91.htm
- DOI: https://dx.doi.org/10.4254/wjh.v16.i1.91